Acquisition strengthens early-stage drug development

Symeres, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), has acquired DGr Pharma, a consultancy specialised in early-stage drug development and regulatory strategy. This strategic move strengthens Symeres’ integrated services, enhancing its ability to accelerate IND-enabling processes for biopharma clients across Europe and beyond.

Founded in 2018, DGr Pharma brings deep expertise in preclinical and clinical regulatory planning, quality assurance, and regulatory submissions for small and large molecules, including antibodies, ADCs, and oligonucleotides. By combining Symeres’ existing CRDMO infrastructure with DGr Pharma’s regulatory know-how, the partnership offers a more seamless, end-to-end path from discovery to early clinical development.

Guillaume Jetten, CEO of Symeres, commented: “Acquiring DGr Pharma allows us to deliver a fully integrated development solution, enhancing regulatory support and scientific depth for our clients. This strengthens Symeres’ position as a preferred partner for innovative biopharma companies.”

Kees Groen, Founder and CEO of DGr Pharma, added: “Joining Symeres opens up new opportunities to scale our expertise and broaden the impact we deliver to clients. Together, we can accelerate early-stage development while maintaining our commitment to quality and scientific rigor.”

Supported by Keensight Capital, the acquisition underscores a shared vision of expanding capabilities in high-value drug classes while reinforcing Symeres’ role in the global biopharma ecosystem.

More information online